Clinical and Translational Oncology

, Volume 12, Issue 4, pp 310–314 | Cite as

Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN

  • Ana Custodio
  • Antonio Calles
  • Pedro Pérez-Segura
Case Reports


Glioblastoma multiforme (GBM) is the most aggressive brain tumour in adults and remains incurable despite multimodal intensive treatment regimens. We present a patient with a recurrent glioblastoma who showed coexpression of the epidermal growth factor receptor mutant variant III (EGFRvIII) and the tumour-suppressor protein PTEN. She was treated with the tyrosine kinase inhibitor erlotinib for four months, achieving a partial response with improvement of neurologic symptoms. A review of the pertinent literature supporting the future use of therapies against epidermal growth factor receptor (EGFR) in highgrade gliomas is also provided.


Glioblastoma multiforme Recurrent disease Epidermal growth factor receptor PTEN Tyrosine kinase inhibitors 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Marie Y, Carpentier AF, Omuro AM et al (2005) EGFR tyrosine kinase domain mutations in human gliomas. Neurology 64:1444–1445PubMedGoogle Scholar
  2. 2.
    Toth J, Egervari K, Klekner A et al (2009) Analysis of EGFR gene amplification, protein overexpression and tyrosine kinase domain mutation in recurrent glioblastoma. Pathol Oncol Res 15:225–229CrossRefPubMedGoogle Scholar
  3. 3.
    Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolamide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMedGoogle Scholar
  4. 4.
    Pawson T, Nash P (2003) Assembly of cell regulatory systems through protein interaction domains. Science 300:445–452CrossRefPubMedGoogle Scholar
  5. 5.
    Sawyers CL (2003) Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 17:2998–3010CrossRefPubMedGoogle Scholar
  6. 6.
    Dancey JE, Freidlin B (2003) Targeting epidermal growth factor receptor: are we missing the mark? Lancet 362:62–64CrossRefPubMedGoogle Scholar
  7. 7.
    Sugawa N, Yamamoto K, Ueda S et al (1998) Function of aberrant EGFR in malignant gliomas. Brain Tumor Pathol 15:53–57CrossRefPubMedGoogle Scholar
  8. 8.
    Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139CrossRefPubMedGoogle Scholar
  9. 9.
    Rich JN, Reardon DA, Peery T et al (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133–142CrossRefPubMedGoogle Scholar
  10. 10.
    Rich JN, Rasheed BK, Yan H (2004) EGFR mutations and sensitivity to gefitinib. N Engl J Med 351:1260CrossRefPubMedGoogle Scholar
  11. 11.
    Smith JS, Tachibana I, Passe SM et al (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246–1256CrossRefPubMedGoogle Scholar
  12. 12.
    Nishikawa R, Sugiyama T, Narita Y et al (2004) Immunohistochemical analysis of the mutant epidermal growth factor receptor, deltaEGFR, in glioblastoma. Brain Tumor Pathol 21:53–56CrossRefPubMedGoogle Scholar
  13. 13.
    Luwor RB, Zhu HJ, Walker F et al (2004) The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cell survival and heterodimerizes with the wild-type EGFR. Oncogene 23:6095–6104CrossRefPubMedGoogle Scholar
  14. 14.
    Aldape KD, Ballman K, Furth A et al (2004) Immunohistochemical detection of EGFRvIII in high malignancy grade III astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63:700–707PubMedGoogle Scholar
  15. 15.
    Lammering G, Valerie K, Lin PS et al (2004) Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol 72:267–273CrossRefPubMedGoogle Scholar
  16. 16.
    Heimberger AB, Hlatky R, Suki D et al (2005) Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 15:1462–1466CrossRefGoogle Scholar
  17. 17.
    Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung-cancer activate anti-apoptotic pathways. Science 305:1163–1167CrossRefPubMedGoogle Scholar
  18. 18.
    Li B, Yuan M, Kim IA et al (2004) Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene 23:4594–4602CrossRefPubMedGoogle Scholar
  19. 19.
    Weinstein IB (2002) Addiction to oncogenes: the Achilles heal of cancer. Science 297:63–64CrossRefPubMedGoogle Scholar
  20. 20.
    Choe G, Horvath S, Cloughesy TF et al (2003) Analysis of the phosphatidylinositol-3′ kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63:2742–2746PubMedGoogle Scholar
  21. 21.
    Ermoian RP, Furniss CS, Lamborn KR et al (2002) Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res 8:1100–1106PubMedGoogle Scholar
  22. 22.
    Bianco R, Shin I, Ritter CA et al (2003) Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22:2812–2822CrossRefPubMedGoogle Scholar
  23. 23.
    Prados MD, Lamborn KR, Chang S et al (2006) Phase I study of erlotinib HCl alone and combined with temozolamide in patients with stable or recurrent malignant glioma. Neuro Oncol 8:67–78CrossRefPubMedGoogle Scholar
  24. 24.
    Vogelbaum MA, Peereboom D, Stevens GHJ et al (2004) Response rate to single agent therapy with the EGFR tyrosine kinase inhibitor erlotinib in recurrent glioblastoma multiforme. Results of a phase II study. Neuro Oncol 6:384 (Abstr TA-59)Google Scholar
  25. 25.
    Mellinghoff IK, Wang MY, Vivanco I et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024CrossRefPubMedGoogle Scholar
  26. 26.
    Prados MD, Chang SM, Butowsky N et al (2009) Phase II study of erlotinib plus temozolamide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 27:579–584CrossRefPubMedGoogle Scholar
  27. 27.
    Van den Bent MJ, Brandes AA, Rampling R et al (2009) Randomized phase II trial of erlotinib versus temozolamide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group Study 26034. J Clin Oncol 27:1268–1274CrossRefPubMedGoogle Scholar
  28. 28.
    Chakravarti A, Loeffler JS, Dyson NJ et al (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primaty human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200–207PubMedGoogle Scholar
  29. 29.
    Löw S, Vougioukas VI, Hielscher T et al (2008) Pathogenic pathways leading to glioblatoma multiforme: association between gene expressions and resistance to erlotinib. Anticancer Res 28:3729–3772PubMedGoogle Scholar
  30. 30.
    Reardon D, Cloughesy T, Conrad C et al (2005) A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases in recurrent GBM patients. J Clin Oncol 23:207s (Abs 3063)CrossRefGoogle Scholar
  31. 31.
    Huang PH, Mukasa A, Bonavia R et al (2007) Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 104:12867–12872CrossRefPubMedGoogle Scholar
  32. 32.
    Janmaat ML, Kruyt FA, Rodríguez JA et al (2003) Response to epidermal growth factor receptor inhibitors in nonsmall cell lung cancer: limited antiproliferative effect and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9:2316–2326PubMedGoogle Scholar
  33. 33.
    Magne N, Fischel JL, Dubreuil A et al (2006) Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (“Iressa”). Br J Cancer 86:1518–1523CrossRefGoogle Scholar
  34. 34.
    Stommel JM, Kimmelman AC, Ying H et al (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287–290CrossRefPubMedGoogle Scholar
  35. 35.
    Huang PH, Mukasa A, Bonavia R et al (2007) Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 104:12867–12872CrossRefPubMedGoogle Scholar
  36. 36.
    Neshat MS, Mellinghoff IK, Tran C et al (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98:10314–10319CrossRefPubMedGoogle Scholar
  37. 37.
    Goudar RK, Shi Q, Hjelmeland MD et al (2005) Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4:101–112PubMedGoogle Scholar
  38. 38.
    Sampaio C, Dance M, Montagner A et al (2008) Signal strength dictates phosphoinositide 3-kinase contribution to Ras/extracellular signal-regulated kinase 1 and 2 activation via differential Gab1/Shp2 recruitment: consequences for resistance to epidermal growth factor receptor inhibition. Mol Cell Biol 28:587–600CrossRefPubMedGoogle Scholar
  39. 39.
    Yamasaki F, Johansen MJ, Zhang D et al (2007) Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 67:5779–5788CrossRefPubMedGoogle Scholar
  40. 40.
    Gericke A, Munson M, Ross AH (2006) Regulation of PTEN phosphatase. Gene 374: 1–9CrossRefPubMedGoogle Scholar

Copyright information

© Feseo 2010

Authors and Affiliations

  • Ana Custodio
    • 1
  • Antonio Calles
    • 1
  • Pedro Pérez-Segura
    • 1
  1. 1.Medical Oncology DepartmentHospital Universitario Clínico San CarlosMadridSpain

Personalised recommendations